CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Metformin/Gliclazide Fixed Combination +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03467945
NCT03467945Phase 1Completed

Randomized, Open Label, Single Dose, 4 Treatment, 4 Period, Crossover Design (4 x 4) Trial to Evaluate the Bioequivalence and Secondarily Drug - Drug Interaction of Fixed Combination of Metformin Tablets 1000 mg/Gliclazide 30 mg MR, Compared With the Co-administration of Individual Tablets and Individual Administration of Each Single Tablet (Metformin 1000 mg XR and Gliclazide 30 mg MR) in Healthy Volunteers

Merck KGaA, Darmstadt, Germany·interventional·Posted Mar 16, 2018·Updated Jul 16, 2019

In Brief

A Phase 1 clinical trial evaluating Metformin/Gliclazide Fixed Combination, Metformin, and 1 other intervention for Healthy. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study investigated the bioequivalence and drug-drug interaction of Metformin/Gliclazide fixed combination tablet compared to co-administration of individual tablets of Metformin and Gliclazide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 16, 2018
Enrollment StartFeb 16, 2018
Primary CompletionApr 29, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.3 years ago

Interventions

Metformin/Gliclazide Fixed Combinationdrug

Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.

Metformindrug

Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.

Gliclazidedrug

Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.